Current pediatric osteologyReview articles

M. Bayer

Clin Osteol 2009; 14(2): 39-40

Diagnosing osteoporosis in childrenReview articles

Z. Šumník, O. Souček

Clin Osteol 2009; 14(2): 41-48

Aetiopathogenesis of osteoporosis is significantly different in children than in adults. Children most commonly present with seconda­ ry osteoporosis due to chronic diseases and/or their treatment. In children, low bone density is diagnosed following DXA findings and fracture history. When considering potential therapy, in addition to bone density parameters and history, the expected development of bone quality or strength should be individually assessed, with respect to the activity of the underlying disease and its therapy. DXA findings should always be interpreted with respect to anthropometric parameters, in particular the height and stage of puberty,...

Osteogenesis imperfecta in children - what attending physicians should knowReview articles

M. Bayer

Clin Osteol 2009; 14(2): 49-57

Osteogenesis imperfecta is a group of genetically determined disorders, commonly known as brittle bone disease. Osteogenesis im­ perfecta occurs once in every 10,000 to 30,000 births. Most cases are caused by mutation in the genes encoding type I collagen. Less than one tenth of cases are caused by mutations in other genes. Clinical manifestations of the disease are highly variable, from a mild form to a lethal course during the perinatal period. Knowledge about osteogenesis imperfecta and its treatment significantly increased during recent years. Several new types of the disease have been identified since the first classification was introduced by...

Bone metabolism disorders in children with nephrotic syndromeReview articles

J. Feber, P. Geier

Clin Osteol 2009; 14(2): 58-62

The article deals with the adverse effects that glucocorticoid therapy has on the bones of children with nephrotic syndrome. Special attention is paid to growth disorders, alterations in bone density and pathological fractures in this population. Glucocorticoids nega­ tively affect bone metabolism, in particular by suppressing bone formation and affecting the activity of osteoclasts. This was better un­ derstood by studying the osteoprotegerin (OPG)/RANK-ligand/RANK triad. Through inhibition of OPG and subsequent stimulation of RANK-L expression in osteoblasts, glucocorticoids stimulate osteoclastogenesis. The available literary data suggest that bone...

Hypercalciuria in childrenInformations

S. Skálová, Š. Kutílek

Clin Osteol 2009; 14(2): 63-69

News from around the worldLiterature

Clin Osteol 2009; 14(2): 70-73

Osteology Centre, Košice - Šaca a. s. HospitalNews

S.Tomková, Z. Beličáková

Clin Osteol 2009; 14(2): 74

FRAX Slide Kit IOF launches educational slide kit to enhance understanding of FRAX®News

Clin Osteol 2009; 14(2): 75

XII. International Congress of the Czech and Slovak Society for Metabolic Bone DiseaseAbstracts

Clin Osteol 2009; 14(2): 76